On 5 MAY Columbia Laboratories Inc. (NASDAQ:CBRX) reported $0.01 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.07 by $0.06. The company had revenue of $7.20 million for the quarter, compared to the consensus estimate of $6.30 million. Analysts expect that Columbia Laboratories will post $0.41 EPS for the current fiscal year. Columbia Laboratories Inc. (NASDAQ:CBRX) net profit margin is 23.50% and weekly performance is 1.55%. On last trading day company shares ended up $6.55. Analysts mean target price for the company is $10.00. Columbia Laboratories Inc. (NASDAQ:CBRX) distance from 50-day simple moving average (SMA50) is -4.37%.
On 13 MAY pSivida Corp. (NASDAQ:PSDV) presented the first peer-reviewed, in-vitro data for Tethadur™, pSivida’s technology designed to provide sustained delivery of peptides, proteins and antibodies, demonstrating sustained delivery of Avastin with Tethadur. pSivida Corp. (NASDAQ:PSDV) shares fell -1.61% in last trading session and ended the day on $3.66. PSDV return on assets is -62.10%. pSivida Corp. (NASDAQ:PSDV) quarterly performance is -18.30%.
On 17 MAY Bio-Path Holdings Inc (NASDAQ:BPTH) announced operational and financial results for the first quarter ended March 31, 2014. Operating expenses of $510,210 in the first quarter of 2014 were lower by $145,700 compared to the first quarter of 2013. As of March 31, 2014, the Company had cash of $16,819,783, compared to $3,551,832 at December 31, 2013. Net cash used in operating activities for the first three months of 2014 was $544,422 compared to $551,004 for the first three months of 2013. Increases in cash for working capital in the three month period ending March 31, 2014 substantially offset a lower net loss compared to the three month period ending March 31, 2013.Bio-Path Holdings Inc (NASDAQ:BPTH) shares moved down -0.74% in last trading session and was closed at $2.68, while trading in range of $2.67 – $2.74. Bio-Path Holdings Inc (NASDAQ:BPTH) year to date (YTD) performance is -33.00%.
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) ended the last trading day at $5.74. Company weekly volatility is calculated as 8.39% and price to cash ratio as 12.79. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) showed a negative weekly performance of -15.46%.
On 23 MAY Alkermes Plc (NASDAQ:ALKS) reported $0.11 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.10 by $0.01. The company had revenue of $130.21 million for the quarter, compared to the consensus estimate of $135.79 million. During the same quarter in the prior year, the company posted $0.40 earnings per share. The company’s quarterly revenue was down 20.3% on a year-over-year basis. Alkermes Plc (NASDAQ:ALKS) net profit margin is 3.50% and weekly performance is 4.59%. On last trading day company shares ended up $45.59. Analysts mean target price for the company is $50.92. Alkermes Plc (NASDAQ:ALKS) distance from 50-day simple moving average (SMA50) is 1.65%.